Funke H J, Moritz E, Hellstern K, Malanowski H
Alsterdorfer Anstalt, Hamburg, Federal Republic of Germany.
Acta Psychiatr Scand Suppl. 1990;360:46-7. doi: 10.1111/j.1600-0447.1990.tb05326.x.
Moclobemide was compared with clomipramine for safety and efficacy in 2 groups of 15 patients each with endogenous depression. The drugs were given under double-blind conditions in increasing doses; 1 patient in the moclobemide group dropped out because of lack of efficacy. Mean final improvement on the Hamilton Rating Scale for Depression was 51% in the moclobemide group and 54% in the clomipramine group. Efficacy and tolerance were rated good or very good by 47% (moclobemide) and 53% (clomipramine) (NS). The results indicate that moclobemide is as effective as clomipramine in treating endogenous depression.
将吗氯贝胺与氯米帕明进行对比，研究二者对两组各15例内源性抑郁症患者的安全性和疗效。药物在双盲条件下递增剂量给药；吗氯贝胺组有1例患者因无效退出。抑郁症汉密尔顿评定量表的平均最终改善率在吗氯贝胺组为51%，氯米帕明组为54%。47%（吗氯贝胺）和53%（氯米帕明）的患者将疗效和耐受性评为良好或非常好（无显著性差异）。结果表明，吗氯贝胺在治疗内源性抑郁症方面与氯米帕明疗效相当。
